Daiichi Sankyo, Yakult, And Generics Get Approval For Irinotecan Additional Indication Of Pediatric Malignancy
This article was originally published in PharmAsia News
Daiichi Sankyo, Yakult, Sawai, and Hospira Japan received approval for an irinotecan additional indication for pediatric malignant solid tumors.
You may also be interested in...
Infogram: OTC firms should start thinking about post-COVID-19 business strategy, SEMPORA Consulting GmbH suggests, based on a recent survey on the impact of the coronavirus on German OTC companies.
With hospitals throughout the EU short of urgently needed COVID-19 medical supplies, including respiratory equipment, there are ways for companies to sell and deliver their products quickly.